Tsuruo T
Institute of Molecular and Cellular Biosciences, University of Tokyo.
Gan To Kagaku Ryoho. 1994 Jun;21(7):962-7.
Since we discovered verapamil as an MDR-reversing agent in 1981, many MDR-reversing compounds have been reported. This type of drug must be very effective but minimal side effects. We recently found that MS-209 and PSC-833 to be reversing agents that interact directly with P-glycoprotein and show good MDR-reversing effect, both in vitro and in vivo. MS-209 and PSC-833 are thus interesting compounds for clinical use in future.
自1981年我们发现维拉帕米是一种多药耐药逆转剂以来，已有许多多药耐药逆转化合物被报道。这类药物必须非常有效但副作用最小。我们最近发现MS - 209和PSC - 833是能直接与P -糖蛋白相互作用的逆转剂，在体外和体内均显示出良好的多药耐药逆转效果。因此，MS - 209和PSC - 833是未来临床上令人感兴趣的化合物。
